Yaz Australia (also known as drospirenone/ethinyl estradiol tablets) is an oral contraceptive with light pink active film-coated tablets, which is prescribed for women to prevent pregnancy. Each tablet contains 3 mg of drospirenone and 0.02 mg of ethinyl estradiol stabilized by betadex as a clathrate (molecular complex).
In addition, Yaz is prescribed for the treatment of premenstrual dysphoric disorder (PMDD) symptoms among women, who prefer using oral contraception. The effectiveness of Yaz as PMDD treatment for period of more than three menstrual cycles has not been studied in details yet.
Yaz can also be used for the treatment of moderate acne vulgaris among women of minimum 14 years old, unless they have certain contraindications to oral contraceptive therapy. Yaz should be indicated as acne treatment only in cases if the patient prefers an oral contraceptive as birth control.
Different patients have been studied and monitored during and after the period of taking Yaz Australia in order to come up with the general list of possible adverse reactions and side effects of Yaz. Please consult with your doctor in order to avoid any possible complications or problems.
Yaz Australia should be taken with care in order to ensure that no harm to patient’s health had been done. Likewise, stop taking Yaz Australia if an arterial or venous thrombotic (VTE) event are observed. Hereby, prior to taking Yaz Australia if you are a new COC (oral contraceptive) user or if you are a woman, who is changing a contraceptive not containing DRSP, please make sure to consider all risks and benefits of a DRSP-containing COC in terms of risks of a VTE. Basic risk factors of VTE are: obesity, smoking, family history of VTE, as well as other factors prohibiting the use of COCs.
Yaz Australia contains 3 mg of progestin DRSP, which includes anti-mineralocorticoid activity, as well as has the potential for hyperkalemia in high-risk patients. Yaz is prohibited for patients who have conditions predisposed to hyperkalemia (i.e. hepatic impairment, renal impairment, adrenal insufficiency etc.). Women undergoing daily, long-term treatment for chronic conditions as well as diseases with medications, which can increase serum potassium concentration, should necessarily check the serum potassium concentration during the very first treatment cycle.
Women with breast cancer (or who have previously had breast cancer) should abstain from taking Yaz Australia, since breast cancer is a hormonally-sensitive tumor. There are evidences proving that COCs don’t increase the likelihood of breast cancer. Although some past studies have shown that COCs might cause an increase the breast cancer likelihood, recent studies haven’t confirmed such facts and findings.
However, it is still advised to keep close monitoring of your health conditions with your physician prior to, during and after the cycle of taking Yaz Australia. In order to purchase or receive a more detailed information about Yaz Australia, please get in touch with customer support and check the detailed description.